Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.62 |
| ▸ | CTSK | P43235 | 6/20 | 0.62 |
| ▸ | CTSL | P07711 | 2/20 | 0.62 |
| ▸ | CTSB | P07858 | 2/20 | 0.62 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | CAPN9 | O14815 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12653615 | 1.00 | CTSS (0.62) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL12653865 | 1.00 | CTSS (0.62) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL19391054 | 0.90 | CTSS (0.50) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL22273529 | 0.90 | CAPN1 (0.49) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL18941377 | 0.89 | CTSS (0.68) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL7302264 | 0.89 | CTSS (0.68) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL17449484 | 0.86 | CTSS (0.68) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL28969921 | 0.86 | CTSS (0.68) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL16329168 | 0.83 | CAPN1 (0.70) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL9889092 | 0.82 | CTSK (0.67) | CTSSCTSKCTSLCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200237849-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2020-07-30 | — | — | US | disclosed |
| US-20190015472-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2019-01-17 | — | — | US | disclosed |
| US-10022418-B2 | Compositions and methods for treating beta-amyloid related diseases | AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3296295-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | American Life Science Pharmaceuticals, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-2921486-B1 | Compositions and methods for treating beta-amyloid related diseases | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20160058824-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2921486-A1 | Compositions and methods for treating beta-amyloid related diseases | American Life Science Pharmaceuticals, Inc. (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-2462131-B1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2462131-A2 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | American Life Science Pharmaceuticals Inc., (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20110105603-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| WO-2011017600-A2 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (ALSP INC.) (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105603-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | APP, BACE1, PTMS | CTSS 111/4885CTSK 979/4885CTSL 82/4885 |
| US-10022418-B2 | Compositions and methods for treating beta-amyloid related diseases | APP, BACE1, PTMS | CTSS 111/4885CTSK 979/4885CTSL 82/4885 |
| US-20200237849-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | APP, BACE1, PTMS | CTSS 111/4885CTSK 979/4885CTSL 82/4885 |
| US-20190015472-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | APP, BACE1, PTMS | CTSS 111/4885CTSK 979/4885CTSL 82/4885 |
| US-20160058824-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | APP, BACE1, PTMS | CTSS 111/4885CTSK 979/4885CTSL 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.